Diamond Hill Capital Management Inc. Reduces Stock Holdings in Humana Inc. (NYSE:HUM)

Diamond Hill Capital Management Inc. decreased its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 2.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,337 shares of the insurance provider's stock after selling 1,957 shares during the period. Diamond Hill Capital Management Inc. owned about 0.07% of Humana worth $22,051,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Riverview Trust Co acquired a new position in shares of Humana in the 1st quarter valued at $34,000. Garde Capital Inc. acquired a new position in Humana during the first quarter worth approximately $36,000. Transce3nd LLC purchased a new position in shares of Humana during the fourth quarter worth about $38,000. Whipplewood Advisors LLC increased its position in Humana by 639.1% in the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after acquiring an additional 147 shares during the period. Finally, Colonial Trust Advisors lifted its position in Humana by 4,500.0% during the 4th quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider's stock worth $47,000 after acquiring an additional 180 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

Humana stock traded up $9.01 during trading on Friday, reaching $238.22. The company had a trading volume of 1,569,145 shares, compared to its average volume of 1,505,668. The firm's 50-day simple moving average is $234.56 and its 200 day simple moving average is $256.19. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $406.09. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $28.75 billion, a price-to-earnings ratio of 16.85, a price-to-earnings-growth ratio of 1.63 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. The firm's revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted $7.23 earnings per share. Sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on HUM shares. Robert W. Baird dropped their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday. Barclays set a $268.00 price target on Humana and gave the stock an "equal weight" rating in a research note on Thursday, June 12th. Guggenheim started coverage on shares of Humana in a research note on Wednesday, April 9th. They set a "buy" rating and a $326.00 price objective for the company. Mizuho boosted their target price on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Finally, Truist Financial cut their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a research note on Wednesday, July 16th. Sixteen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $282.43.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.